Overview

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

Status:
Active, not recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Glycine
Ixazomib